Drugs / uracil-tegafur
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00152178 | Jul 1996 → Apr 2008 | breast cancer | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | uracil-tegafur | “It has been reported that treatment with uracil-tegafur (UFT) has shown significantly better survival and relapse-free survival (RFS) than surgery alone.” PMID 19638976 ↗ Jul 2009 |
| Known as | UFT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00152178 ↗ |
| Route | Oral | “UFT(uracil, tegafur:270 mg/m2/day (p.o.) for 2 years)” NCT00152178 ↗ |